Kooperativer Bibliotheksverbund

UID:

Format: 1 online resource (602 pages)

Edition: First edition.

ISBN: 0-323-95115-5

Content: Molecular Biomarkers in Cancer Detection and Monitoring of Therapeutics: Volume Two: Diagnostic and Therapeutic Applications discusses how molecular biomarkers are used to determine predisposition, facilitate detection, improve treatment and offer prevention guidelines for different cancers. It focuses on novel diagnostic techniques based on molecular biomarkers and their impact on treatment, covering different cancer types such as tumors in the nervous system, head and neck, oral and GI tractor, lung, breast, gastric system, leukemia and urogenital tract cancers. For each type, the book discusses the best diagnostic techniques and therapeutic approaches, thus helping readers easily identify the best solution for each case.

Note: Intro -- Biomarkers in Cancer Detection and Monitoring of Therapeutics: Volume 2: Diagnostic and Therapeutic Applications -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Oral squamous cell carcinoma -- 1. Oral cancer -- 2. Oral squamous cell carcinoma -- 3. Epidemiology -- 4. Etiology -- Impact of tobacco products -- Patterns and trends in tobacco use -- Use of smokeless tobacco products -- 5. Precursor lesions -- 5.1. Genetically acquired potentially malignant disorders -- 5.2. Tobacco-induced potentially malignant disorders -- 5.3. Immune-mediated potentially malignant disorders -- 5.4. Genetically inherited potentially malignant disorders -- 6. Oral epithelial dysplasia -- 7. Pathogenesis -- 7.1. Autophagy -- 8. Cancer stem cells -- 9. Tumor microenvironment -- 10. Epithelial-mesenchymal transition -- 11. Metastasis -- 12. Oral bacteria in oral carcinogenesis -- 13. Clinical features -- Salient features specific to subsite -- 14. Diagnosis -- 14.1. Adjunctive aids for early detection -- Nano-diagnostics -- Lab-on-chip/microfluidics -- Liquid biopsy -- Microarray technology -- Next generation sequencing -- Omics -- Genomics -- Transcriptomics -- Proteomics -- Metabolomics -- Staging of oral squamous cell carcinoma -- 15. Histopathological features -- 16. Treatment -- 16.1. Surgical resection -- Management of primary lesion -- Management of neck nodes -- 16.2. Chemotherapy -- Adjuvant chemotherapy -- Adjuvant chemoradiotherapy -- Primary chemoradiation -- Induction chemotherapy -- In the management of metastatic disease -- 16.3. Nanotechnology in carcinoma therapy -- Chemoprevention using nanoparticles -- 16.4. Radiotherapy -- 16.5. Immunotherapy -- Cytokines -- Toll-like receptors -- Immune checkpoint inhibitors -- Immune checkpoint activators -- 16.6. Therapeutic markers -- 17. Prognosis -- 17.1. Clinical factors. , 17.2. Histopathological factors -- 17.3. Metastasis -- References -- Chapter Two: Genetic predisposition and pathophysiology of oral squamous cell carcinoma -- 1. Introduction -- 1.1. Microbial flora -- 1.2. Oral microbial flora -- 1.3. Oral microbial flora and cancer -- 1.4. Squamous cell carcinoma of the head and neck -- 2. Oral squamous cell carcinoma and glucose transporters -- 2.1. Human glucose transporters -- 2.2. Glucose transporters (GLUT 1) and its expression -- 3. Oral squamous cell carcinoma and methylated genes -- 3.1. Variation of methylated genes in cancer conditions -- 3.2. DNA methylation modifications and its implications -- References -- Chapter Three: Molecular biomarkers in gastric cancer -- 1. Introduction -- 2. RNF43 -- 3. APC -- 4. ARID1A -- 5. ARID2 -- 6. MSI -- 7. MALTA1-GLT1 fusion -- 8. TP53 -- 9. RB1 -- 10. ERBB2 -- 11. C-MET -- 12. EGFR -- 13. PD-L1 -- 14. Epstein-Barr virus -- 15. VEGF-A -- 16. CD44 -- 17. E-cadherin -- 18. Matrix metalloproteinases (MMPs) -- 19. Conclusions -- References -- Chapter Four: Recent advancement in molecular markers of pancreatic cancer -- 1. Introduction -- 2. Blood markers -- 3. DNA and RNA markers -- 4. Serum markers -- 5. Serum carbohydrate antigen (CA) CA19-9 -- 6. Glycosylation -- 7. Mucins -- 8. Genetic markers -- 9. Oncogenic KRAS -- 10. Tumor suppressor genes -- 11. CDKN2A -- 12. TP53 -- 13. SMAD4 -- 14. Epigenetic markers -- 15. DNA methylation changes -- 16. Micro RNA modification -- 17. Pancreatic tumor juice markers -- 18. Proteomics -- 19. Growth factors and receptors -- 20. Mitochondrial mutations -- 21. Telomerase -- 22. M2-pyruvate kinase -- 23. Microarray -- 24. Pancreatic tumor tissue markers -- 25. Precancerous lesions -- 26. Cystic fluid -- 27. Screening and diagnosis of pancreatic cancer -- 28. Recent imaging strategies -- 29. Conclusion -- Acknowledgment -- References. , Chapter Five: Molecular biomarkers in pancreatic ductal adenocarcinoma -- 1. Introduction -- 2. Metabolic reprograming -- 3. Biomarkers for diagnosis -- 3.1. Carbohydrate antigen 19-9 (CA19-9) -- 3.2. Micro-RNAs -- 3.3. Cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) -- 3.4. Extracellular vesicles (EVs) -- 3.5. DNA methylation -- 3.6. PAM4 -- 3.7. Leukemia inhibitory factor (LIF) -- 4. Prognostic biomarkers -- 4.1. CA19-9 -- 4.2. microRNA -- 4.3. Circulating tumor cells (CTCs), cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA) -- 4.4. Extracellular vesicles (EVs) -- 4.5. DNA methylation -- 4.6. Human equilibrative nucleoside transporter 1 (hENT1) -- 4.7. Human concentrative nucleoside transporters 3 (hCNT3) -- 4.8. Deoxycytidine kinase (dCK), ribonucleotide reductase M1 (RRM1) -- 4.9. Dihydropyrimidine dehydrogenase (DPD) -- 4.10. Carboxylesterase 2 (CES2) -- 5. Targeted therapy -- 5.1. PARP -- 5.2. PD-1 -- 5.3. EGFR -- 5.4. KRAS -- 5.5. NTRK -- 5.6. ALK -- 5.7. CDKN2A -- 6. Conclusions -- References -- Chapter Six: Biomarkers in endocrine diseases -- 1. Introduction -- 2. Basic biomarkers -- 2.1. Thyroid -- 2.2. Disorders related to calcium and bone metabolism -- 2.3. Adrenal -- 2.4. Endocrine pancreas including diabetes and neuroendocrine tumors (NET) of gastrointestinal tract -- 2.5. Others (pituitary and reproductive glands) -- 3. Modern biomarkers (including molecular markers) -- 3.1. Thyroid -- 3.2. Parathyroid -- 3.3. Adrenal -- 3.4. NET -- 3.5. Others -- References -- Chapter Seven: Cancer immunotherapy-associated endocrine complications and treatment strategies -- 1. Introduction -- 2. Immune checkpoints and its function -- 2.1. CTLA-4 -- 2.2. PD1 -- 3. Immune checkpoint inhibitors -- 4. Functional mechanism and efficacy of immune checkpoint inhibitors -- 5. Cancer immunotherapy with ICIs and associated endocrinopathies. , 5.1. Hypophysitis -- 5.2. Thyroiditis -- 5.3. Diabetes mellitus -- 5.4. Primary adrenal insufficiency (PAI) -- 6. Screening, management and treatment strategies -- 7. Conclusion and future directions -- References -- Chapter Eight: Shared and distinct aspects of hematopoietic malignancies such as leukemia and lymphoma -- 1. Introduction -- 2. Leukemia -- 2.1. Acute myeloid leukemia (AML) -- 2.2. Acute lymphoid leukemia (ALL) -- 2.3. Chronic myeloid leukemia (CML) -- 2.4. Chronic lymphoid leukemia (CLL) -- 3. Lymphoma -- 3.1. Hodgkin lymphoma -- 3.2. Non-Hodgkin lymphoma -- 4. Conclusion -- Acknowledgment -- References -- Chapter Nine: Molecular diagnosis, drivers, and treatment modalities for chronic lymphocytic leukemia -- 1. Introduction -- 2. Diagnosis/detection of CLL -- 3. Molecular drivers of CLL -- 4. Treatment modalities for the CLL disease -- 5. Intratumor heterogeneity and clonal evolution of CLL -- 6. Future directions -- Acknowledgments -- References -- Chapter Ten: Myelodysplastic syndrome: A challenging entity -- 1. Pathogenesis -- 2. Clinical presentation -- 3. Classification -- 3.1. MDS with single lineage dysplasia (MDS-SLD) -- Genetics -- Prognosis -- 3.2. MDS with multiple lineage dysplasia (MDS-MLD) -- Genetics -- Prognosis -- 3.3. MDS with ring sideroblasts (MDS-RS) -- Genetics -- Prognosis -- 3.4. MDS with excess of blasts -- Genetics -- Prognosis -- 3.5. MDS with isolated del(5q) -- Genetics -- Prognosis -- 3.6. MDS-U -- Genetics -- Prognosis -- 3.7. Refractory cytopenia of childhood (RCC) -- Genetics -- 4. Approach to diagnosis of MDS -- 4.1. Complete blood count (CBC) -- 4.2. Peripheral blood film (PBF) -- 4.3. Bone marrow examination -- 4.4. Bone marrow biopsy -- 4.5. Differential diagnoses -- 4.6. MDS scoring system -- 4.7. Treatment of MDS -- References -- Chapter Eleven: Multiple myeloma -- 1. Etiopathogenesis. , 2. Clinical features -- 3. Diagnosis -- 4. Radiographic evaluation -- 5. Histology -- 6. Prognosis -- 7. Treatment -- 7.1. There are two purposes of the therapy -- 7.2. Supportive treatment -- References -- Chapter Twelve: Role of biomarkers in assessing response to immune checkpoint inhibitors in cancer treatment -- 1. Introduction -- 1.1. Immune checkpoint inhibitors -- 1.2. Approved checkpoint inhibitors -- 2. Predictive biomarkers to assess response to checkpoint inhibitor therapy -- 2.1. Pretreatment biomarkers -- Tissue biomarkers -- PD-L1 expression on tumor cells -- Tumor mutation burden -- Microsatellite instability (MSI) and DNA mismatch repair (MMR) -- Tumor-infiltrating lymphocytes (TIL) -- Host germline genetics -- Host-related biomarkers -- General characteristics -- 2.2. Posttreatment biomarkers -- Blood biomarkers -- Lactate dehydrogenase (LDH) -- C-reactive protein (CRP) -- Differential blood count markers -- Peripheral T-cell biomarkers -- Soluble serum biomarkers (cytokines) -- Liquid biopsy biomarkers -- Biomarkers of circulating tumor DNA (ctDNA) -- Other circulating molecular biomarkers -- 2.3. Stool biomarkers -- Gut microbiome profile -- 2.4. Immune-related adverse events (irAEs) -- 3. Summary -- References -- Chapter Thirteen: Molecular biomarkers in prostate cancer -- 1. Introduction -- 2. Molecular biomarkers used for diagnosis (Table 1) -- 2.1. Blood-based molecular biomarkers -- 2.2. Urine-based molecular biomarkers -- 2.3. Tissue-based molecular biomarkers -- 3. Molecular biomarkers used for treatment (Table 2) -- 3.1. Gatekeeper-type tumor suppressor genes -- 3.2. Caretaker-type tumor suppressor genes -- 3.3. mRNA-based genomic biomarkers -- 3.4. Androgen receptor splice variant 7 (AR-v7) -- 4. Future prospects -- 4.1. micro-RNA (miRNA) -- 4.2. Biomarkers for antibody-drug conjugates (ADCs) -- 5. Conclusion. , References.

Additional Edition: Print version: Sobti, Ranbir Chander Biomarkers in Cancer Detection and Monitoring of Therapeutics San Diego : Elsevier Science & Technology,c2023 ISBN 9780323951142

Language: English

UID:

Format: 1 online resource (602 pages)

Edition: First edition.

ISBN: 0-323-95115-5

Content: Molecular Biomarkers in Cancer Detection and Monitoring of Therapeutics: Volume Two: Diagnostic and Therapeutic Applications discusses how molecular biomarkers are used to determine predisposition, facilitate detection, improve treatment and offer prevention guidelines for different cancers. It focuses on novel diagnostic techniques based on molecular biomarkers and their impact on treatment, covering different cancer types such as tumors in the nervous system, head and neck, oral and GI tractor, lung, breast, gastric system, leukemia and urogenital tract cancers. For each type, the book discusses the best diagnostic techniques and therapeutic approaches, thus helping readers easily identify the best solution for each case.

Note: Intro -- Biomarkers in Cancer Detection and Monitoring of Therapeutics: Volume 2: Diagnostic and Therapeutic Applications -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Oral squamous cell carcinoma -- 1. Oral cancer -- 2. Oral squamous cell carcinoma -- 3. Epidemiology -- 4. Etiology -- Impact of tobacco products -- Patterns and trends in tobacco use -- Use of smokeless tobacco products -- 5. Precursor lesions -- 5.1. Genetically acquired potentially malignant disorders -- 5.2. Tobacco-induced potentially malignant disorders -- 5.3. Immune-mediated potentially malignant disorders -- 5.4. Genetically inherited potentially malignant disorders -- 6. Oral epithelial dysplasia -- 7. Pathogenesis -- 7.1. Autophagy -- 8. Cancer stem cells -- 9. Tumor microenvironment -- 10. Epithelial-mesenchymal transition -- 11. Metastasis -- 12. Oral bacteria in oral carcinogenesis -- 13. Clinical features -- Salient features specific to subsite -- 14. Diagnosis -- 14.1. Adjunctive aids for early detection -- Nano-diagnostics -- Lab-on-chip/microfluidics -- Liquid biopsy -- Microarray technology -- Next generation sequencing -- Omics -- Genomics -- Transcriptomics -- Proteomics -- Metabolomics -- Staging of oral squamous cell carcinoma -- 15. Histopathological features -- 16. Treatment -- 16.1. Surgical resection -- Management of primary lesion -- Management of neck nodes -- 16.2. Chemotherapy -- Adjuvant chemotherapy -- Adjuvant chemoradiotherapy -- Primary chemoradiation -- Induction chemotherapy -- In the management of metastatic disease -- 16.3. Nanotechnology in carcinoma therapy -- Chemoprevention using nanoparticles -- 16.4. Radiotherapy -- 16.5. Immunotherapy -- Cytokines -- Toll-like receptors -- Immune checkpoint inhibitors -- Immune checkpoint activators -- 16.6. Therapeutic markers -- 17. Prognosis -- 17.1. Clinical factors. , 17.2. Histopathological factors -- 17.3. Metastasis -- References -- Chapter Two: Genetic predisposition and pathophysiology of oral squamous cell carcinoma -- 1. Introduction -- 1.1. Microbial flora -- 1.2. Oral microbial flora -- 1.3. Oral microbial flora and cancer -- 1.4. Squamous cell carcinoma of the head and neck -- 2. Oral squamous cell carcinoma and glucose transporters -- 2.1. Human glucose transporters -- 2.2. Glucose transporters (GLUT 1) and its expression -- 3. Oral squamous cell carcinoma and methylated genes -- 3.1. Variation of methylated genes in cancer conditions -- 3.2. DNA methylation modifications and its implications -- References -- Chapter Three: Molecular biomarkers in gastric cancer -- 1. Introduction -- 2. RNF43 -- 3. APC -- 4. ARID1A -- 5. ARID2 -- 6. MSI -- 7. MALTA1-GLT1 fusion -- 8. TP53 -- 9. RB1 -- 10. ERBB2 -- 11. C-MET -- 12. EGFR -- 13. PD-L1 -- 14. Epstein-Barr virus -- 15. VEGF-A -- 16. CD44 -- 17. E-cadherin -- 18. Matrix metalloproteinases (MMPs) -- 19. Conclusions -- References -- Chapter Four: Recent advancement in molecular markers of pancreatic cancer -- 1. Introduction -- 2. Blood markers -- 3. DNA and RNA markers -- 4. Serum markers -- 5. Serum carbohydrate antigen (CA) CA19-9 -- 6. Glycosylation -- 7. Mucins -- 8. Genetic markers -- 9. Oncogenic KRAS -- 10. Tumor suppressor genes -- 11. CDKN2A -- 12. TP53 -- 13. SMAD4 -- 14. Epigenetic markers -- 15. DNA methylation changes -- 16. Micro RNA modification -- 17. Pancreatic tumor juice markers -- 18. Proteomics -- 19. Growth factors and receptors -- 20. Mitochondrial mutations -- 21. Telomerase -- 22. M2-pyruvate kinase -- 23. Microarray -- 24. Pancreatic tumor tissue markers -- 25. Precancerous lesions -- 26. Cystic fluid -- 27. Screening and diagnosis of pancreatic cancer -- 28. Recent imaging strategies -- 29. Conclusion -- Acknowledgment -- References. , Chapter Five: Molecular biomarkers in pancreatic ductal adenocarcinoma -- 1. Introduction -- 2. Metabolic reprograming -- 3. Biomarkers for diagnosis -- 3.1. Carbohydrate antigen 19-9 (CA19-9) -- 3.2. Micro-RNAs -- 3.3. Cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) -- 3.4. Extracellular vesicles (EVs) -- 3.5. DNA methylation -- 3.6. PAM4 -- 3.7. Leukemia inhibitory factor (LIF) -- 4. Prognostic biomarkers -- 4.1. CA19-9 -- 4.2. microRNA -- 4.3. Circulating tumor cells (CTCs), cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA) -- 4.4. Extracellular vesicles (EVs) -- 4.5. DNA methylation -- 4.6. Human equilibrative nucleoside transporter 1 (hENT1) -- 4.7. Human concentrative nucleoside transporters 3 (hCNT3) -- 4.8. Deoxycytidine kinase (dCK), ribonucleotide reductase M1 (RRM1) -- 4.9. Dihydropyrimidine dehydrogenase (DPD) -- 4.10. Carboxylesterase 2 (CES2) -- 5. Targeted therapy -- 5.1. PARP -- 5.2. PD-1 -- 5.3. EGFR -- 5.4. KRAS -- 5.5. NTRK -- 5.6. ALK -- 5.7. CDKN2A -- 6. Conclusions -- References -- Chapter Six: Biomarkers in endocrine diseases -- 1. Introduction -- 2. Basic biomarkers -- 2.1. Thyroid -- 2.2. Disorders related to calcium and bone metabolism -- 2.3. Adrenal -- 2.4. Endocrine pancreas including diabetes and neuroendocrine tumors (NET) of gastrointestinal tract -- 2.5. Others (pituitary and reproductive glands) -- 3. Modern biomarkers (including molecular markers) -- 3.1. Thyroid -- 3.2. Parathyroid -- 3.3. Adrenal -- 3.4. NET -- 3.5. Others -- References -- Chapter Seven: Cancer immunotherapy-associated endocrine complications and treatment strategies -- 1. Introduction -- 2. Immune checkpoints and its function -- 2.1. CTLA-4 -- 2.2. PD1 -- 3. Immune checkpoint inhibitors -- 4. Functional mechanism and efficacy of immune checkpoint inhibitors -- 5. Cancer immunotherapy with ICIs and associated endocrinopathies. , 5.1. Hypophysitis -- 5.2. Thyroiditis -- 5.3. Diabetes mellitus -- 5.4. Primary adrenal insufficiency (PAI) -- 6. Screening, management and treatment strategies -- 7. Conclusion and future directions -- References -- Chapter Eight: Shared and distinct aspects of hematopoietic malignancies such as leukemia and lymphoma -- 1. Introduction -- 2. Leukemia -- 2.1. Acute myeloid leukemia (AML) -- 2.2. Acute lymphoid leukemia (ALL) -- 2.3. Chronic myeloid leukemia (CML) -- 2.4. Chronic lymphoid leukemia (CLL) -- 3. Lymphoma -- 3.1. Hodgkin lymphoma -- 3.2. Non-Hodgkin lymphoma -- 4. Conclusion -- Acknowledgment -- References -- Chapter Nine: Molecular diagnosis, drivers, and treatment modalities for chronic lymphocytic leukemia -- 1. Introduction -- 2. Diagnosis/detection of CLL -- 3. Molecular drivers of CLL -- 4. Treatment modalities for the CLL disease -- 5. Intratumor heterogeneity and clonal evolution of CLL -- 6. Future directions -- Acknowledgments -- References -- Chapter Ten: Myelodysplastic syndrome: A challenging entity -- 1. Pathogenesis -- 2. Clinical presentation -- 3. Classification -- 3.1. MDS with single lineage dysplasia (MDS-SLD) -- Genetics -- Prognosis -- 3.2. MDS with multiple lineage dysplasia (MDS-MLD) -- Genetics -- Prognosis -- 3.3. MDS with ring sideroblasts (MDS-RS) -- Genetics -- Prognosis -- 3.4. MDS with excess of blasts -- Genetics -- Prognosis -- 3.5. MDS with isolated del(5q) -- Genetics -- Prognosis -- 3.6. MDS-U -- Genetics -- Prognosis -- 3.7. Refractory cytopenia of childhood (RCC) -- Genetics -- 4. Approach to diagnosis of MDS -- 4.1. Complete blood count (CBC) -- 4.2. Peripheral blood film (PBF) -- 4.3. Bone marrow examination -- 4.4. Bone marrow biopsy -- 4.5. Differential diagnoses -- 4.6. MDS scoring system -- 4.7. Treatment of MDS -- References -- Chapter Eleven: Multiple myeloma -- 1. Etiopathogenesis. , 2. Clinical features -- 3. Diagnosis -- 4. Radiographic evaluation -- 5. Histology -- 6. Prognosis -- 7. Treatment -- 7.1. There are two purposes of the therapy -- 7.2. Supportive treatment -- References -- Chapter Twelve: Role of biomarkers in assessing response to immune checkpoint inhibitors in cancer treatment -- 1. Introduction -- 1.1. Immune checkpoint inhibitors -- 1.2. Approved checkpoint inhibitors -- 2. Predictive biomarkers to assess response to checkpoint inhibitor therapy -- 2.1. Pretreatment biomarkers -- Tissue biomarkers -- PD-L1 expression on tumor cells -- Tumor mutation burden -- Microsatellite instability (MSI) and DNA mismatch repair (MMR) -- Tumor-infiltrating lymphocytes (TIL) -- Host germline genetics -- Host-related biomarkers -- General characteristics -- 2.2. Posttreatment biomarkers -- Blood biomarkers -- Lactate dehydrogenase (LDH) -- C-reactive protein (CRP) -- Differential blood count markers -- Peripheral T-cell biomarkers -- Soluble serum biomarkers (cytokines) -- Liquid biopsy biomarkers -- Biomarkers of circulating tumor DNA (ctDNA) -- Other circulating molecular biomarkers -- 2.3. Stool biomarkers -- Gut microbiome profile -- 2.4. Immune-related adverse events (irAEs) -- 3. Summary -- References -- Chapter Thirteen: Molecular biomarkers in prostate cancer -- 1. Introduction -- 2. Molecular biomarkers used for diagnosis (Table 1) -- 2.1. Blood-based molecular biomarkers -- 2.2. Urine-based molecular biomarkers -- 2.3. Tissue-based molecular biomarkers -- 3. Molecular biomarkers used for treatment (Table 2) -- 3.1. Gatekeeper-type tumor suppressor genes -- 3.2. Caretaker-type tumor suppressor genes -- 3.3. mRNA-based genomic biomarkers -- 3.4. Androgen receptor splice variant 7 (AR-v7) -- 4. Future prospects -- 4.1. micro-RNA (miRNA) -- 4.2. Biomarkers for antibody-drug conjugates (ADCs) -- 5. Conclusion. , References.

Additional Edition: Print version: Sobti, Ranbir Chander Biomarkers in Cancer Detection and Monitoring of Therapeutics San Diego : Elsevier Science & Technology,c2023 ISBN 9780323951142

Language: English

UID:

Format: 1 online resource (602 pages)

Edition: First edition.

ISBN: 0-323-95115-5

Content: Molecular Biomarkers in Cancer Detection and Monitoring of Therapeutics: Volume Two: Diagnostic and Therapeutic Applications discusses how molecular biomarkers are used to determine predisposition, facilitate detection, improve treatment and offer prevention guidelines for different cancers. It focuses on novel diagnostic techniques based on molecular biomarkers and their impact on treatment, covering different cancer types such as tumors in the nervous system, head and neck, oral and GI tractor, lung, breast, gastric system, leukemia and urogenital tract cancers. For each type, the book discusses the best diagnostic techniques and therapeutic approaches, thus helping readers easily identify the best solution for each case.

Note: Intro -- Biomarkers in Cancer Detection and Monitoring of Therapeutics: Volume 2: Diagnostic and Therapeutic Applications -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: Oral squamous cell carcinoma -- 1. Oral cancer -- 2. Oral squamous cell carcinoma -- 3. Epidemiology -- 4. Etiology -- Impact of tobacco products -- Patterns and trends in tobacco use -- Use of smokeless tobacco products -- 5. Precursor lesions -- 5.1. Genetically acquired potentially malignant disorders -- 5.2. Tobacco-induced potentially malignant disorders -- 5.3. Immune-mediated potentially malignant disorders -- 5.4. Genetically inherited potentially malignant disorders -- 6. Oral epithelial dysplasia -- 7. Pathogenesis -- 7.1. Autophagy -- 8. Cancer stem cells -- 9. Tumor microenvironment -- 10. Epithelial-mesenchymal transition -- 11. Metastasis -- 12. Oral bacteria in oral carcinogenesis -- 13. Clinical features -- Salient features specific to subsite -- 14. Diagnosis -- 14.1. Adjunctive aids for early detection -- Nano-diagnostics -- Lab-on-chip/microfluidics -- Liquid biopsy -- Microarray technology -- Next generation sequencing -- Omics -- Genomics -- Transcriptomics -- Proteomics -- Metabolomics -- Staging of oral squamous cell carcinoma -- 15. Histopathological features -- 16. Treatment -- 16.1. Surgical resection -- Management of primary lesion -- Management of neck nodes -- 16.2. Chemotherapy -- Adjuvant chemotherapy -- Adjuvant chemoradiotherapy -- Primary chemoradiation -- Induction chemotherapy -- In the management of metastatic disease -- 16.3. Nanotechnology in carcinoma therapy -- Chemoprevention using nanoparticles -- 16.4. Radiotherapy -- 16.5. Immunotherapy -- Cytokines -- Toll-like receptors -- Immune checkpoint inhibitors -- Immune checkpoint activators -- 16.6. Therapeutic markers -- 17. Prognosis -- 17.1. Clinical factors. , 17.2. Histopathological factors -- 17.3. Metastasis -- References -- Chapter Two: Genetic predisposition and pathophysiology of oral squamous cell carcinoma -- 1. Introduction -- 1.1. Microbial flora -- 1.2. Oral microbial flora -- 1.3. Oral microbial flora and cancer -- 1.4. Squamous cell carcinoma of the head and neck -- 2. Oral squamous cell carcinoma and glucose transporters -- 2.1. Human glucose transporters -- 2.2. Glucose transporters (GLUT 1) and its expression -- 3. Oral squamous cell carcinoma and methylated genes -- 3.1. Variation of methylated genes in cancer conditions -- 3.2. DNA methylation modifications and its implications -- References -- Chapter Three: Molecular biomarkers in gastric cancer -- 1. Introduction -- 2. RNF43 -- 3. APC -- 4. ARID1A -- 5. ARID2 -- 6. MSI -- 7. MALTA1-GLT1 fusion -- 8. TP53 -- 9. RB1 -- 10. ERBB2 -- 11. C-MET -- 12. EGFR -- 13. PD-L1 -- 14. Epstein-Barr virus -- 15. VEGF-A -- 16. CD44 -- 17. E-cadherin -- 18. Matrix metalloproteinases (MMPs) -- 19. Conclusions -- References -- Chapter Four: Recent advancement in molecular markers of pancreatic cancer -- 1. Introduction -- 2. Blood markers -- 3. DNA and RNA markers -- 4. Serum markers -- 5. Serum carbohydrate antigen (CA) CA19-9 -- 6. Glycosylation -- 7. Mucins -- 8. Genetic markers -- 9. Oncogenic KRAS -- 10. Tumor suppressor genes -- 11. CDKN2A -- 12. TP53 -- 13. SMAD4 -- 14. Epigenetic markers -- 15. DNA methylation changes -- 16. Micro RNA modification -- 17. Pancreatic tumor juice markers -- 18. Proteomics -- 19. Growth factors and receptors -- 20. Mitochondrial mutations -- 21. Telomerase -- 22. M2-pyruvate kinase -- 23. Microarray -- 24. Pancreatic tumor tissue markers -- 25. Precancerous lesions -- 26. Cystic fluid -- 27. Screening and diagnosis of pancreatic cancer -- 28. Recent imaging strategies -- 29. Conclusion -- Acknowledgment -- References. , Chapter Five: Molecular biomarkers in pancreatic ductal adenocarcinoma -- 1. Introduction -- 2. Metabolic reprograming -- 3. Biomarkers for diagnosis -- 3.1. Carbohydrate antigen 19-9 (CA19-9) -- 3.2. Micro-RNAs -- 3.3. Cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) -- 3.4. Extracellular vesicles (EVs) -- 3.5. DNA methylation -- 3.6. PAM4 -- 3.7. Leukemia inhibitory factor (LIF) -- 4. Prognostic biomarkers -- 4.1. CA19-9 -- 4.2. microRNA -- 4.3. Circulating tumor cells (CTCs), cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA) -- 4.4. Extracellular vesicles (EVs) -- 4.5. DNA methylation -- 4.6. Human equilibrative nucleoside transporter 1 (hENT1) -- 4.7. Human concentrative nucleoside transporters 3 (hCNT3) -- 4.8. Deoxycytidine kinase (dCK), ribonucleotide reductase M1 (RRM1) -- 4.9. Dihydropyrimidine dehydrogenase (DPD) -- 4.10. Carboxylesterase 2 (CES2) -- 5. Targeted therapy -- 5.1. PARP -- 5.2. PD-1 -- 5.3. EGFR -- 5.4. KRAS -- 5.5. NTRK -- 5.6. ALK -- 5.7. CDKN2A -- 6. Conclusions -- References -- Chapter Six: Biomarkers in endocrine diseases -- 1. Introduction -- 2. Basic biomarkers -- 2.1. Thyroid -- 2.2. Disorders related to calcium and bone metabolism -- 2.3. Adrenal -- 2.4. Endocrine pancreas including diabetes and neuroendocrine tumors (NET) of gastrointestinal tract -- 2.5. Others (pituitary and reproductive glands) -- 3. Modern biomarkers (including molecular markers) -- 3.1. Thyroid -- 3.2. Parathyroid -- 3.3. Adrenal -- 3.4. NET -- 3.5. Others -- References -- Chapter Seven: Cancer immunotherapy-associated endocrine complications and treatment strategies -- 1. Introduction -- 2. Immune checkpoints and its function -- 2.1. CTLA-4 -- 2.2. PD1 -- 3. Immune checkpoint inhibitors -- 4. Functional mechanism and efficacy of immune checkpoint inhibitors -- 5. Cancer immunotherapy with ICIs and associated endocrinopathies. , 5.1. Hypophysitis -- 5.2. Thyroiditis -- 5.3. Diabetes mellitus -- 5.4. Primary adrenal insufficiency (PAI) -- 6. Screening, management and treatment strategies -- 7. Conclusion and future directions -- References -- Chapter Eight: Shared and distinct aspects of hematopoietic malignancies such as leukemia and lymphoma -- 1. Introduction -- 2. Leukemia -- 2.1. Acute myeloid leukemia (AML) -- 2.2. Acute lymphoid leukemia (ALL) -- 2.3. Chronic myeloid leukemia (CML) -- 2.4. Chronic lymphoid leukemia (CLL) -- 3. Lymphoma -- 3.1. Hodgkin lymphoma -- 3.2. Non-Hodgkin lymphoma -- 4. Conclusion -- Acknowledgment -- References -- Chapter Nine: Molecular diagnosis, drivers, and treatment modalities for chronic lymphocytic leukemia -- 1. Introduction -- 2. Diagnosis/detection of CLL -- 3. Molecular drivers of CLL -- 4. Treatment modalities for the CLL disease -- 5. Intratumor heterogeneity and clonal evolution of CLL -- 6. Future directions -- Acknowledgments -- References -- Chapter Ten: Myelodysplastic syndrome: A challenging entity -- 1. Pathogenesis -- 2. Clinical presentation -- 3. Classification -- 3.1. MDS with single lineage dysplasia (MDS-SLD) -- Genetics -- Prognosis -- 3.2. MDS with multiple lineage dysplasia (MDS-MLD) -- Genetics -- Prognosis -- 3.3. MDS with ring sideroblasts (MDS-RS) -- Genetics -- Prognosis -- 3.4. MDS with excess of blasts -- Genetics -- Prognosis -- 3.5. MDS with isolated del(5q) -- Genetics -- Prognosis -- 3.6. MDS-U -- Genetics -- Prognosis -- 3.7. Refractory cytopenia of childhood (RCC) -- Genetics -- 4. Approach to diagnosis of MDS -- 4.1. Complete blood count (CBC) -- 4.2. Peripheral blood film (PBF) -- 4.3. Bone marrow examination -- 4.4. Bone marrow biopsy -- 4.5. Differential diagnoses -- 4.6. MDS scoring system -- 4.7. Treatment of MDS -- References -- Chapter Eleven: Multiple myeloma -- 1. Etiopathogenesis. , 2. Clinical features -- 3. Diagnosis -- 4. Radiographic evaluation -- 5. Histology -- 6. Prognosis -- 7. Treatment -- 7.1. There are two purposes of the therapy -- 7.2. Supportive treatment -- References -- Chapter Twelve: Role of biomarkers in assessing response to immune checkpoint inhibitors in cancer treatment -- 1. Introduction -- 1.1. Immune checkpoint inhibitors -- 1.2. Approved checkpoint inhibitors -- 2. Predictive biomarkers to assess response to checkpoint inhibitor therapy -- 2.1. Pretreatment biomarkers -- Tissue biomarkers -- PD-L1 expression on tumor cells -- Tumor mutation burden -- Microsatellite instability (MSI) and DNA mismatch repair (MMR) -- Tumor-infiltrating lymphocytes (TIL) -- Host germline genetics -- Host-related biomarkers -- General characteristics -- 2.2. Posttreatment biomarkers -- Blood biomarkers -- Lactate dehydrogenase (LDH) -- C-reactive protein (CRP) -- Differential blood count markers -- Peripheral T-cell biomarkers -- Soluble serum biomarkers (cytokines) -- Liquid biopsy biomarkers -- Biomarkers of circulating tumor DNA (ctDNA) -- Other circulating molecular biomarkers -- 2.3. Stool biomarkers -- Gut microbiome profile -- 2.4. Immune-related adverse events (irAEs) -- 3. Summary -- References -- Chapter Thirteen: Molecular biomarkers in prostate cancer -- 1. Introduction -- 2. Molecular biomarkers used for diagnosis (Table 1) -- 2.1. Blood-based molecular biomarkers -- 2.2. Urine-based molecular biomarkers -- 2.3. Tissue-based molecular biomarkers -- 3. Molecular biomarkers used for treatment (Table 2) -- 3.1. Gatekeeper-type tumor suppressor genes -- 3.2. Caretaker-type tumor suppressor genes -- 3.3. mRNA-based genomic biomarkers -- 3.4. Androgen receptor splice variant 7 (AR-v7) -- 4. Future prospects -- 4.1. micro-RNA (miRNA) -- 4.2. Biomarkers for antibody-drug conjugates (ADCs) -- 5. Conclusion. , References.

Additional Edition: Print version: Sobti, Ranbir Chander Biomarkers in Cancer Detection and Monitoring of Therapeutics San Diego : Elsevier Science & Technology,c2023 ISBN 9780323951142

Language: English

UID:

Format: 1 Online-Ressource(XX, 494 p. 1 illus.)

Edition: 1st ed. 2021.

ISBN: 9789811651052

Content: Chapter1: Corona Viruses: Emergence, Evolution, and Recurrence -- Chapter 2: Testing Strategy of Covid-19: a Mechanistic Approach -- Chapter 3: the Broad Impact of Infectious Disease Epidemics on Human Civilization: a Public Health Perspective -- Chapter 4: Human Impacts on Natural Habitats Leading to Covid-19 Pandemic -- Chapter 5: Transmission of Sars-cov2 and Strategies for Control of Infection – Lessons Learnt -- Chapter 6: Pathogenesis of Covid-19 Infection -- Chapter 7: Pathology of Covid-19 Infection -- Chapter 8: Covid-19: Clinical Spectrum – It’s Multiorgan Syndrome -- Chapter 9: Organ Involvement in Covid 19: Lung and Beyond -- Chapter 10: Covid-19 and Mucormycosis -- Chapter 11: Rhino-orbito-cerebral Mucormycosis-the Bane of the ‘black Fungus’ -- Chapter 12: Strokes, Neurological and Neuropsychiatric Disorders in Covid-19 -- Chapter 13: Insights Into Role of Angiotensin-converting Enzyme 2 in the Onset of Severe Acute Respiratory Syndrome Coronavirus 2 Pathogenesis -- Chapter 14: Immunology and Pathogenesis of Covid-19 -- Chapter 15: Mrna Vaccine: an Advanced and Transformative Technology for Vaccine Development -- Chapter 16: Dampening of Inflammatory Makers and Understanding Covid 19 Viral Disease Development: a Combinattorial Approach -- Chapter 17: Covid-19: New Use of Therapeutics -- Chapter 18: Pharmacological Agents Targeting Coagulopathy in Covid-19: a Review -- Chapter 19: Gut Microbiome in Covid 19: New Insights' -- Chapter 20: Covid-19 Pandemic and Mental Illness: Impact of Gut-microbiota -- Chapter 21: the Psychological Impact of Covid-19 -- Chapter 22: Potential Influence of Parasitic Interactions on Covid-19 Pathology and Epidemiology -- Chapter 23: Plausible Impacts of Sars-cov-2 on Human Reproductive System -- Chapter 24: an Insight Into Association Between Covid-19 Infection and Abo Blood Group -- Chapter 25: Herbal Formulations for the Treatment of Covid-19 -- Chapter 26: Covid-19, Nutrition, Immunity and Diet -- Chapter 27: Challenges Faced in Treating Covid-patients and Lessons Learnt -- Chapter 28: Fears, Challenges and Opportunities During Covid 19: a Frontliner’s Perspective in Health Care System.

Content: This book discusses the organ-specific systemic manifestations of COVID-19. The initial chapters of the book review the origin and evolution of the coronaviruses, followed by pathogenesis and immune response during COVID-19 infection. The book also provides insight into the role of angiotensin-converting enzyme 2 in the onset of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogenesis. It summarizes the neurological aspects of SARS-CoV2, including transmission pathways, mechanisms of invasion into the nervous system, and mechanisms of neurological disease. It also delineates the association of severe disease with high blood plasma levels of inflammatory cytokines and inflammatory markers in SARS-CoV-2 infection. Lastly, it discusses the perturbation of gut microbiota by SARS-CoV-2 and uncovers the potential risk of virus infection on reproductive health.

Additional Edition: ISBN 9789811651045

Additional Edition: ISBN 9789811651069

Additional Edition: ISBN 9789811651076

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9789811651045

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9789811651069

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 9789811651076

Language: English

DOI: 10.1007/978-981-16-5105-2

URL: lizenzpflichtig